This will be a randomized, double-blind, placebo-controlled, dose-ranging, efficacy and
safety study in children with impulsive aggression comorbid with
Attention-Deficit/Hyperactivity Disorder (ADHD). The target subjects are healthy male and
female children aged 6 to 12 years, inclusive, with a diagnosis of ADHD. A total of 120
subjects will be randomized across approximately 30 US centers to one of four treatment
groups.
Minimum age: 6 Years.
Maximum age: 12 Years.
Gender(s): Both.
Dothan, Alabama, United States
Los Angeles, California, United States
Santa Ana, California, United States
Washington, District of Columbia, United States
Bradenton, Florida, United States
Gainesville, Florida, United States
Hialeah, Florida, United States
Jacksonville, Florida, United States
Maitland, Florida, United States
North Miami, Florida, United States
Orlando, Florida, United States
Tampa, Florida, United States
Atlanta, Georgia, United States
Libertyville, Illinois, United States
Indianapolis, Indiana, United States
Terre Haute, Indiana, United States
Owensboro, Kentucky, United States
Toms River, New Jersey, United States
Stony Brook, New York, United States
Cleveland, Ohio, United States
Columbus, Ohio, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Charleston, South Carolina, United States
Memphis, Tennessee, United States
Bellevue, Washington, United States
Bothell, Washington, United States